Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease (Q24200476)

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Tolerance to bronchodilating effects of salmeterol in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Bronchodilation improves endurance but not muscular efficiency in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Tiotropium for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Safety of indacaterol in the treatment of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Self-management education for patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Tiotropium versus placebo for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Pulmonary rehabilitation for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Costs of chronic bronchitis and COPD: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Resource use and risk factors in high-cost exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Review of guidelines for good practice in decision-analytic modelling in health technology assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Beta2-agonist and anticholinergic drugs in the treatment of lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Safety of long-acting beta-agonists in stable COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Smoking cessation for chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

The beta-adrenergic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Pharmacoeconomic Evaluation of Acute Exacerbations of Chronic Bronchitis and COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

St. George's Respiratory Questionnaire: MCID

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

Quality of life changes in COPD patients treated with salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

The beta-adrenoceptor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

The effect of tiotropium on exacerbations and airflow in patients with COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

Long-acting bronchodilators in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009157.PUB2

7 January 2021

10.1002/14651858.CD009157.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

2275717

2275717

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference